Alnylam Pharmaceuticals
ALNY
#637
Rank
NZ$54.74 B
Marketcap
$421.91
Share price
-0.59%
Change (1 day)
40.62%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -NZ$0.3 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$2.09 Billion. In 2023 the company made an earning of -NZ$0.55 Billion, an increase over its 2022 earnings that were of -NZ$1.68 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -NZ$0.3 Billion-45.12%
2023 -NZ$0.55 Billion-67.84%
2022 -NZ$1.68 Billion36.93%
2021 -NZ$1.23 Billion-8.04%
2020 -NZ$1.34 Billion-15.66%
2019 -NZ$1.59 Billion12.23%
2018 -NZ$1.41 Billion62.91%
2017 -NZ$0.87 Billion17.78%
2016 -NZ$0.74 Billion43.44%
2015 -NZ$0.52 Billion60.69%
2014 -NZ$0.32 Billion98.2%
2013 -NZ$0.17 Billion
2011 -NZ$94.8 Million27.48%
2010 -NZ$74.36 Million-10.92%
2009 -NZ$83.48 Million95.77%
2008 -NZ$42.64 Million
2006 -NZ$68.31 Million-9.13%
2005 -NZ$75.18 Million34.74%
2004 -NZ$55.8 Million36.79%
2003 -NZ$40.79 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-NZ$1.01 Billion 210.42%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$8.59 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.22 B-169.24%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$0.21 Billion-36.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$71.54 Million-77.86%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$22.01 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NZ$12.80 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$0.72 B-324.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel